HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader




Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2011 Hyman, Phelps & McNamara, P.C.

Awards & Honors










« Sen. Nelson Introduces Bill to Amend ANDA “First Applicant” Definition that Would Effectively Gut 180-Day Exclusivity; “Reverse Payments” Also Back in the News | Main | Teva Sues FDA Over Generic COZAAR and HYZAAR 180-Day Exclusivity Forfeiture and Patent Delisting Rule »

June 25, 2009

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef01157159cb0e970b

Listed below are links to weblogs that reference The FTC Issues Interim Report on Authorized Generics; Report Examines the Short-Term Effects of Authorized Generics During 180-Day Exclusivity:

Comments

The comments to this entry are closed.